 | • レポートコード：MRC2311A0169 • 出版社/出版日：360iResearch / 2023年10月25日 • レポート形態：英文、PDF、192ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷不可、1年間閲覧） | ￥592,350 (USD3,949) | ▷ お問い合わせ |
| Site License（同一拠点内共有可、印刷可） | ￥1,042,350 (USD6,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 脊髄性筋萎縮症治療市場規模は、2022年に13.9億米ドルと推定され、2023年には16.0億米ドルに達すると予測され、CAGR 15.38%で2030年には43.7億米ドルに達すると予測されます。 市場細分化とカバー範囲： この調査レポートは、脊髄性筋萎縮症治療市場の包括的な見通しを提供するために、様々なサブ市場を分析し、収益を予測し、各カテゴリの新たな動向を調査しています。 ● タイプ別に、タイプ1、タイプ2、タイプ3、タイプ4を調査しています。タイプ4は予測期間中に大きな市場シェアを占めると予測されています。 ● 治療法別では、薬物療法と遺伝子置換療法を調査しています。予測期間中、遺伝子置換療法が大きなシェアを占めると予測されます。 ● 投与経路別では、髄腔内投与と経口投与の市場を調査しています。予測期間中は髄腔内投与が大きなシェアを占めると予測されています。 ● 地域別では、南北アメリカ、アジア太平洋、ヨーロッパ、中東、アフリカで調査を行いました。詳しい内訳は、南北アメリカはアルゼンチン、ブラジル、カナダ、メキシコ、アメリカを対象に、アメリカはさらにカリフォルニア、フロリダ、イリノイ、ニューヨーク、オハイオ、ペンシルバニア、テキサスを対象に調査を行いました。アジア太平洋地域は、オーストラリア、中国、インド、インドネシア、日本、マレーシア、フィリピン、シンガポール、韓国、台湾、タイ、ベトナムでした。ヨーロッパ・中東・アフリカは、デンマーク、エジプト、フィンランド、フランス、ドイツ、イスラエル、イタリア、オランダ、ナイジェリア、ノルウェー、ポーランド、カタール、ロシア、サウジアラビア、南アフリカ、スペイン、スウェーデン、スイス、トルコ、アラブ首長国連邦、イギリスを対象としています。2022年の市場シェアは南北アメリカが38.75%で最大、次いでヨーロッパ、中東・アフリカでした。 市場統計： 本レポートでは、主要7通貨（米ドル、ユーロ、日本円、英ポンド、豪ドル、カナダドル、スイスフラン）の市場規模と予測を提供しています。本レポートでは、2018年から2021年を過去年、2022年を基準年、2023年を推定年、2024年から2030年を予測期間としています。 FPNVポジショニングマトリックス： FPNVポジショニングマトリックスは、脊髄性筋萎縮症治療市場を評価するための不可欠なツールです。事業戦略と製品満足度に関連する主要指標を分析し、ベンダーを包括的に評価します。これにより、ユーザーは特定のニーズに合わせた情報に基づいた意思決定を行うことができます。高度な分析により、ベンダーは4つの象限に分類され、それぞれ成功のレベルが異なります： フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。この洞察に満ちたフレームワークにより、意思決定者は自信を持って市場をナビゲートすることができます。 市場シェア分析： 市場シェア分析では、脊髄性筋萎縮症治療市場のベンダーランドスケープに関する貴重な洞察を提供します。全体的な収益、顧客基盤、その他の主要指標に対する影響を評価することで、各社の業績と直面している競争環境について包括的な理解を提供します。この分析では、調査期間中の市場シェア獲得、断片化、優位性、業界再編などの競争レベルも明らかにします。 主要企業のプロフィール： 本レポートでは、脊髄性筋萎縮症治療市場における最近の重要な動向を掘り下げ、主要ベンダーとその革新的なプロフィールを紹介しています。これには、Astellas Pharma Inc., Biogen Inc., Catalyst Pharmaceuticals, Inc., Cytokinetics, Incorporated, F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Natera Inc., NMD PHARMA A/S, Novartis AG, Novo Nordisk A/S, PerkinElmer, Inc., Pfizer Inc., PTC Therapeutics, Inc., Scholar Rock, Inc., and Takeda Pharmaceutical Company Limited.などが含まれます。 本レポートでは、以下の点について貴重な洞察を提供しています： 1. 市場浸透： 主要企業の市場ダイナミクスと製品に関する包括的な情報を提供します。 2. 市場開拓： 新興市場と成熟市場セグメントへの浸透を詳細に分析し、有利な機会を強調します。 3. 市場の多様化： 新製品の発売、未開拓の地域、最近の開発、投資に関する詳細情報を記載しています。 4. 競合他社の評価とインテリジェンス： 主要企業の市場シェア、戦略、製品、認証、規制当局の承認、特許状況、製造能力を網羅的に評価しています。 5. 製品開発とイノベーション： 将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を行いました。 本レポートは、以下のような主要な質問に対応しています： 1. 脊髄性筋萎縮症治療市場の市場規模および予測はどのようになっていますか？ 2. 脊髄性筋萎縮症治療市場で最も高い投資ポテンシャルを持つ製品、セグメント、用途、分野はどこですか？ 3. 脊髄性筋萎縮症治療市場の機会を特定するための競争戦略窓口はどのようになっていますか？ 4. 脊髄性筋萎縮症治療市場における最新の技術動向と規制の枠組みはどのようになっていますか？ 5. 脊髄性筋萎縮症治療市場における主要ベンダーの市場シェアはどのようになっていますか？ 6. 脊髄性筋萎縮症治療市場への参入に適したモードと戦略的動きはどのようになっていますか？ |
1. 序論
2. 調査方法
3. エグゼクティブサマリー
4. 市場概要
5. 市場インサイト
6. 脊髄性筋萎縮症治療の市場分析：種類別
7. 脊髄性筋萎縮症治療の市場分析：治療法別
8. 脊髄性筋萎縮症治療の市場分析：投与経路別
9. 南北アメリカの脊髄性筋萎縮症治療市場
10. アジア太平洋の脊髄性筋萎縮症治療市場
11. ヨーロッパ・中東・アフリカの脊髄性筋萎縮症治療市場
12. 競争状況
13. 競争ポートフォリオ
14. 付録
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Spinal Muscular Atrophy Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising burden of spinal muscular atrophy
5.1.1.2. Favorable reimbursements for spinal muscular atrophy treatment
5.1.1.3. Awareness programs initiatives by government and nonprofit organizations
5.1.2. Restraints
5.1.2.1. Limited time-window for successful therapy delivery
5.1.3. Opportunities
5.1.3.1. R&D for expanding possibilities of spinal muscular atrophy treatment efficacy
5.1.3.2. Expansion of online medication distribution channels
5.1.4. Challenges
5.1.4.1. Shortage of trained professionals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Spinal Muscular Atrophy Treatment Market, by Type
6.1. Introduction
6.2. Type 1
6.3. Type 2
6.4. Type 3
6.5. Type 4
7. Spinal Muscular Atrophy Treatment Market, by Treatment
7.1. Introduction
7.2. Drug Therapy
7.3. Gene Replacement Therapy
8. Spinal Muscular Atrophy Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intrathecal
8.3. Oral
9. Americas Spinal Muscular Atrophy Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Spinal Muscular Atrophy Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Spinal Muscular Atrophy Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Astellas Pharma Inc.
13.1.2. Biogen Inc.
13.1.3. Catalyst Pharmaceuticals, Inc.
13.1.4. Cytokinetics, Incorporated
13.1.5. F. Hoffmann-La Roche Ltd.
13.1.6. Ionis Pharmaceuticals, Inc.
13.1.7. Natera Inc.
13.1.8. NMD PHARMA A/S
13.1.9. Novartis AG
13.1.10. Novo Nordisk A/S
13.1.11. PerkinElmer, Inc.
13.1.12. Pfizer Inc.
13.1.13. PTC Therapeutics, Inc.
13.1.14. Scholar Rock, Inc.
13.1.15. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
TABLE 3. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 6. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE 4, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 11. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GENE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 14. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 17. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 20. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 21. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 23. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 26. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 28. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 31. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 41. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 43. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 64. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. THAILAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 81. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. DENMARK SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. EGYPT SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 88. FINLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 94. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 100. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 109. NORWAY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. POLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 115. QATAR SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 127. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 136. TURKEY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 144. SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 145. SPINAL MUSCULAR ATROPHY TREATMENT MARKET LICENSE & PRICING